Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Pregabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 1.00 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pregabalin SCHEMBL1561104 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL8227 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL15497 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL27754092 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2370227 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2966808 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL4608711 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL17825547 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL19031786 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL3371102 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240035092-A1 | METHODS, KITS, AND SYSTEMS FOR PREDICTING PATIENT OUTCOMES | SAPERE BIO, INC. | 2024-02-01 | — | — | US | claimed |
| WO-2022125857-A1 | METHODS, KITS, AND SYSTEMS FOR PREDICTING PATIENT OUTCOMES | SAPERE BIO, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | claimed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | claimed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | claimed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | claimed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | claimed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | claimed |
| US-6329429-B1 | ADMINISTERING ANTI-INFLAMMATORY COMPOUND COMPRISING CYCLIC AMINO ACID OR ITS DERIVATIVE TO THERAPY | WARNER-LAMBERT COMPANY | 2001-12-11 | — | — | US | claimed |
| US-20010016665-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL) -5- METHYLHEXANOIC ACID | GROTE TODD MICHEL (US) | 2001-08-23 | — | — | US | claimed |
| US-20010014698-A1 | Method for preventing and treating alcoholism | BUENO LIONEL (FR) | 2001-08-16 | — | — | US | claimed |
| US-6140366-A | ANTICONVULSANT THERAPY FOR CENTRAL NERVOUS SYSTEM DISORDERS, E.G., EPILEPSY, HUNTINGTON'S CHOREA, CEREBRAL ISCHEMIA, PARKINSON'S DISEASE, TARDIVE DYSKINESIA, ANTISPASMODIC AND PSYCHOTIC DISORDERS; ANTIDEPRESSANT, ANXIOLYTIC AGENTS | NORTHWESTERN UNIVERSITY (US) | 2000-10-31 | — | — | US | claimed |
| US-6127418-A | USING, E.G. PREGABALAN, GAGAPENTIN, FOR A PATIENT WHO IS OR WILL RECEIVE NSAID THERAPY OR ALCOHOL ABUSE THERAPY; INFLAMMATORY BOWEL DISORDER; IRRITABLE BOWEL SYNDROME; CROHN'S DISEASE, ILEITIS, ISCHEMIC BOWEL DISEASE | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0974351-A2 | Medicament for preventing and treating gastrointestinal damage | JOUVEINAL (FR) | 2000-01-26 | — | — | EP | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0830338-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996040617-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
| US-20010016665-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL) -5- METHYLHEXANOIC ACID | APEH, CA6, ALKBH3 | CACNA2D1 1710/4885CACNB3 1216/4885CACNA1C 669/4885 |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | CACNA2D1 3541/4885CACNB3 1477/4885CACNA1C 2966/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-20010014698-A1 | Method for preventing and treating alcoholism | ADH1A, GABRB3, GABRB2 | CACNA2D1 700/4885CACNB3 47/4885CACNA1C 137/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.